Curr Rheumatol Rev. 2026 Mar 13. doi: 10.2174/0115733971409871251206061614. Online ahead of print.
ABSTRACT
INTRODUCTION: Rheumatoid arthritis is a chronic autoimmune disorder characterized by persistent inflammation, synovial hyperplasia, and joint destruction. Despite advances in biologics and disease-modifying antirheumatic drugs, treatment challenges remain due to incomplete responses, adverse effects, and high costs. This has spurred interest in natural bioactive compounds as multi-target therapeutic agents.
METHODS: A comprehensive review of preclinical and clinical studies was conducted to evaluate the mechanisms of action, therapeutic potential, limitations, and formulation strategies of natural bioactive compounds for rheumatoid arthritis management.
RESULTS: natural bioactive compounds derived from plant, marine, and microbial sources, including polyphenols, flavonoids, alkaloids, and terpenoids, exhibit anti-inflammatory, antioxidant, immunomodulatory, and antiproliferative effects. They modulate key rheumatoid arthritis pathways, including NF-κB, JAK/STAT, MAPK, and Nrf2, while restoring immune balance through Th17/Treg regulation. Preclinical studies show efficacy in reducing cytokine storms, oxidative stress, and fibroblast-like synoviocyte proliferation. Clinical trials with curcumin, resveratrol, and boswellic acids demonstrated improvements in disease activity, pain, and inflammatory biomarkers. However, poor bioavailability and variability in extracts remain major limitations.
DISCUSSION: Emerging nanotechnology-based delivery systems have enhanced the stability and absorption of natural bioactive compounds. While natural bioactive compounds demonstrate lower toxicity and potential to complement conventional therapies, challenges persist regarding standardization, dosing, and reproducibility. Large-scale, well-designed trials are still needed to validate their clinical utility compared to biologics.
CONCLUSION: Current evidence suggests that natural bioactive compounds hold promise as safe, multi-target adjuncts that may complement existing Rheumatoid arthritis therapies and improve overall disease management, but further rigorous clinical validation is essential.
PMID:41837510 | DOI:10.2174/0115733971409871251206061614